Scientists at USC Michelson Center for Convergent Bioscience and Japan’s Nagoya University find and test a promising drug that stops cancer by interfering with the cancer cells’ metabolism and other circadian-related functions
A new drug shows potential to halt cancer cells’ growth by stunting the cells’ biological clock.
The findings from scientists at the USC Michelson Center for Convergent Bioscience and Nagoya University’s Institute of Transformative BioMolecules (ITbM) advance a burgeoning area of research: turning the body’s circadian rhythms against cancer.
Their study, conducted on human kidney cancer cells and on acute myeloid leukemia in mice, was published Jan. 23 in the journal Science Advances.
Scientists know that disrupting sleep and other elements of humans’ circadian rhythm can harm health. The same is true for the circadian clock of cells themselves. If researchers could disturb the circadian clock of cancer cells, they theorize, they could potentially hurt or kill those cells.
The scientists found that a molecule named GO289 targets an enzyme that controls the cell’s circadian rhythm. This drug-protein interaction then disrupts the functions of four other proteins that are important for cell growth and survival.
Human bone cancer cells stopped growing when a drug molecule jammed their circadian rhythm during a study that appears in Science Advances. Photo courtesy of the Kay lab at the USC Michelson Center for Convergent Bioscience.
In effect, GO289 can jam the cogs of the cell’s circadian clock, slowing its cycles. And it can do so with little impact to healthy cells.
“In some cancers, the disease takes over the circadian clock mechanism and uses it for the evil purpose of helping itself grow,” said Steve Kay, director of convergent biosciences at the USC Michelson Center and USC Provost Professor of Neurology, Biomedical Engineering and Biological Sciences. “With GO289, we can interfere with those processes and stop the cancer from growing.”
Kay is among several scientists from USC Dornsife College of Letters, Arts and Sciences, USC Viterbi School of Engineering and Keck School of Medicine of USC who are collaborating across multiple disciplines to find new solutions for treating cancer, neurological disease and cardiovascular disease.
Finding the right candidate
On its initial interactions with human bone cancer cells, GO289 appeared to slow the tumors’ circadian clock as it targeted an enzyme, named CK2.
To see if GO289 consistently hindered other cancers in the same way, the scientists then tested it on human kidney cancer cells and on mice with acute myeloid leukemia. They found that GO289 specifically affected cancer cell metabolism and other circadian-related functions that normally would enable the cancer to grow and spread.
Kay is optimistic about the findings. “This could become an effective new weapon that kills cancer,” he said.
The Latest on: Cancer
via Google News
The Latest on: Cancer
- Girl with terminal cancer who received thousands of cards from dogs passes awayon November 19, 2019 at 3:02 am
A little girl with cancer, who captured the hearts of thousands of people with her love for dogs, has died. Emma Mertens, 8, of Hartland, Wisconsin, died peacefully at home Sunday afternoon, ...
- India-Made Anti-Cancer Device Cytotron Gets ‘Breakthrough’ Designation From US FDAon November 19, 2019 at 2:48 am
The anti-cancer device, Cytotron, developed by Bangalore-based Rajah Vijay Kumar received a “breakthrough” designation from the U.S. FDA’s Center for Devices and Radiological Health for the treatment ...
- Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumabon November 19, 2019 at 2:42 am
Nivolumab improves the prognosis of non-small cell lung cancer (NSCLC) but can cause immune-related adverse events (irAEs). Reports have indicated longer progression-free survivals (PFSs) in patients ...
- Ollie Gardiner: Cancer teen's family donates treatment funds to researchon November 18, 2019 at 4:47 pm
A man who promised his dying teenage son he would find a cure for the type of cancer he had has donated nearly £200,000 to help fund research. Ollie Gardiner, 13, died on 19 November 2017 after ...
- Why Hasn’t Immunotherapy Been Working For Prostate Cancer? Bone Tumors May Be The Answeron November 18, 2019 at 4:00 pm
Researchers from MD Anderson in Texas have uncovered new clues as to why immunotherapy may fail in ... [+] many men with prostate cancer. Immunotherapy drugs called immune checkpoint inhibitors have ...
- New screening method identifies inhibitors of cancer cell metabolismon November 18, 2019 at 1:54 pm
A new screening system developed by scientists at the UCLA Jonsson Comprehensive Cancer Center leverages redundancy in an important component of a cell—nucleotide metabolism—to help identify new drugs ...
- Expert: Herbal aids can slow wound healing in breast cancer spread to skinon November 18, 2019 at 10:20 am
Using herbal products to treat breast cancer that's spread to the skin could slow wound healing and interfere with chemotherapy or hormone treatment, an expert warns. Many patients try herbal products ...
- Matthew Glaetzer: ‘I'm treating this like a little injury. Cancer won’t hold me back’on November 18, 2019 at 9:00 am
Photograph: Dean Mouhtaropoulos/Getty Images “It definitely rocks you.” Australian track cycling star Matthew Glaetzer is reflecting on a “whirlwind” month that has seen his preparations for the 2020 ...
- The mutational footprints of cancer therapieson November 18, 2019 at 8:09 am
Some cancer therapies damage DNA and cause mutations in both cancerous and healthy cells. Therapy-induced mutations may underlie some of the long-term and late side effects of treatments, such as ...
- GEST Foundation brings financial aid to cancer patientson November 18, 2019 at 8:04 am
Alex Briceno, pictured with his wife, Gail, received a GEST Foundation grant to help pay for some of his expenses from his treatment for colorectal cancer. Alex Briceno, pictured with his wife, Gail, ...
via Bing News